Welcome to our dedicated page for Waldencast plc SEC filings (Ticker: WALDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Waldencast plc (WALDW) SEC filings page on Stock Titan provides access to regulatory documents filed by this beauty and wellness operating platform as a foreign private issuer. Waldencast plc files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934.
Available Form 6-K filings show how the company uses these reports to share business and regulatory developments. One Form 6-K indicates that Waldencast plc issued a press release describing strong progress on business priorities for a half-year period and initiatives to drive transformation, with the press release attached as an exhibit. Another Form 6-K states that the company announced FDA approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel under the Obagi Medical brand, again with the related announcement attached as an exhibit.
On this page, users can review such Form 6-K submissions, which may include press releases and other materials related to the Obagi Medical and Milk Makeup segments. Because WALDW represents warrants of Waldencast plc, these filings help clarify the regulatory and business context of the underlying issuer.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of each document in plain language. Users can quickly understand the focus of a Form 6-K, identify references to regulatory approvals or business priorities, and navigate to exhibits such as press releases. Real-time updates from EDGAR help ensure that new Waldencast plc filings, including future Form 20-F annual reports or additional Form 6-K current reports, are incorporated as they become available.
Waldencast plc submitted a Form 6-K to furnish a company announcement dated September 10, 2025. The announcement, attached as Exhibit 99.1, states that Waldencast has received FDA approval for the Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel under the Obagi Medical brand.
The report clarifies that this information is being furnished, not filed, and will only be incorporated into other securities filings if specifically referenced.
Waldencast plc is reported to have three related reporting persons holding a common stake in its Class A ordinary shares. The filings show FVF Participacoes Ltda. beneficially holds 7,013,199 shares (approximately 6.1% of the class), while Annapurna Investment Fund Ltd. and Antonio Carlos de Freitas Valle each report 7,013,119 shares (approximately 6.1% of the class). All reported holdings reflect shared voting and shared dispositive power, with no sole voting or dispositive power reported. The percent calculations include 112,644,711 outstanding Class A shares plus 1,611,133 shares deemed outstanding from warrants.
Fitpart Fund Administration Services Ltd. reported beneficial ownership of 5,006,511 Class A ordinary shares of Waldencast plc, representing 4.4% of the class based on 112,026,440 outstanding shares plus 1,555,534 warrants deemed outstanding.
The filing states those shares are directly owned by advisory clients of Fitpart and that no single advisory client is known to beneficially own more than 5% of the Class A shares. The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest, and certifies the holdings were not acquired to influence control of the issuer.
Waldencast plc submitted a Form 6-K to share that it issued a press release on August 18, 2025 providing business and financial updates for the first half of 2025. The release highlights strong progress on key business priorities and outlines initiatives designed to drive the company’s broader transformation.